pubmed-article:16198656 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C2349001 | lld:lifeskim |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C0152035 | lld:lifeskim |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C0681850 | lld:lifeskim |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C1706203 | lld:lifeskim |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C2697811 | lld:lifeskim |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C0017628 | lld:lifeskim |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C0001721 | lld:lifeskim |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C0851347 | lld:lifeskim |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C1332828 | lld:lifeskim |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C1332829 | lld:lifeskim |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C1550501 | lld:lifeskim |
pubmed-article:16198656 | lifeskim:mentions | umls-concept:C1882417 | lld:lifeskim |
pubmed-article:16198656 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:16198656 | pubmed:dateCreated | 2005-10-3 | lld:pubmed |
pubmed-article:16198656 | pubmed:abstractText | Although cytochrome P450 (CYP) 2C9 was thought to be the main pathway for glyburide (INN, glibenclamide) metabolism in vivo, studies in vitro indicated that CYP2C19 had a more dominant effect. This study investigated the relative influence of CYP2C9 and CYP2C19 genotypes on the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. | lld:pubmed |
pubmed-article:16198656 | pubmed:language | eng | lld:pubmed |
pubmed-article:16198656 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16198656 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:16198656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16198656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16198656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16198656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16198656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16198656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16198656 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16198656 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:16198656 | pubmed:month | Oct | lld:pubmed |
pubmed-article:16198656 | pubmed:issn | 0009-9236 | lld:pubmed |
pubmed-article:16198656 | pubmed:author | pubmed-author:TomlinsonBria... | lld:pubmed |
pubmed-article:16198656 | pubmed:author | pubmed-author:YinOphelia... | lld:pubmed |
pubmed-article:16198656 | pubmed:author | pubmed-author:ChowMoses S... | lld:pubmed |
pubmed-article:16198656 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:16198656 | pubmed:volume | 78 | lld:pubmed |
pubmed-article:16198656 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:16198656 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:16198656 | pubmed:pagination | 370-7 | lld:pubmed |
pubmed-article:16198656 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:meshHeading | pubmed-meshheading:16198656... | lld:pubmed |
pubmed-article:16198656 | pubmed:year | 2005 | lld:pubmed |
pubmed-article:16198656 | pubmed:articleTitle | CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. | lld:pubmed |
pubmed-article:16198656 | pubmed:affiliation | School of Pharmacy and Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong. qpyin@cuhk.edu.hk | lld:pubmed |
pubmed-article:16198656 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:16198656 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:16198656 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
entrez-gene:1557 | entrezgene:pubmed | pubmed-article:16198656 | lld:entrezgene |
entrez-gene:1559 | entrezgene:pubmed | pubmed-article:16198656 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:16198656 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:16198656 | lld:entrezgene |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16198656 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16198656 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16198656 | lld:pubmed |